Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

4.7K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.7K
Functions of Thyroid Hormones01:18

Functions of Thyroid Hormones

2.8K
The thyroid hormone (TH) plays a pivotal role in the intricate orchestration of physiological processes, exerting profound effects on development, metabolism, and homeostasis throughout different life stages.
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
2.8K
Drug Therapy01:28

Drug Therapy

60
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
60
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

190
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
190
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Longitudinal, Real-World Study of the Relationship between Levothyroxine Dose and Suboptimal Hypothyroidism Treatment.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Impact of Hypothyroidism on Short-Term and Long-Term Outcomes of Coronary Artery Bypass Graft Surgery.

Thyroid : official journal of the American Thyroid Association·2026
Same author

A Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine Sodium for the Treatment of Hypothyroidism in Adults.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Overnutrition in mice impairs thyroid hormone biosynthesis and utilization, causing hypothyroidism, despite remarkable thyroidal adaptations.

The Journal of clinical investigation·2026
Same author

Thyroid Hormone Synthesis Without Thyroglobulin.

Thyroid : official journal of the American Thyroid Association·2026
Same author

Response to Letter to the Editor from Hedberg et al: "Treatment of Hypothyroidism That Contains Liothyronine Is Associated With Reduced Risk of Dementia and Mortality".

The Journal of clinical endocrinology and metabolism·2025

Related Experiment Video

Updated: Jul 16, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.7K

Emerging Therapies in Hypothyroidism.

Antonio C Bianco1

  • 1Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, University of Chicago School of Medicine, Chicago, Illinois, USA;

Annual Review of Medicine
|September 22, 2023
PubMed
Summary

Levothyroxine (LT4) monotherapy is insufficient for some hypothyroidism patients. Combination LT4 and liothyronine (LT3) therapy offers improved quality of life and cognition, with new formulations and regenerative approaches showing promise.

Keywords:
combination therapyhypothyroidismlevothyroxineliothyronineresidual symptoms

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.1K

Related Experiment Videos

Last Updated: Jul 16, 2025

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.7K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.1K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Regenerative Medicine

Background:

  • Levothyroxine (LT4) is the standard treatment for hypothyroidism.
  • A subset of patients remain symptomatic despite normalized thyrotropin levels on LT4 therapy.
  • Alternative therapeutic strategies are needed for these individuals.

Purpose of the Study:

  • To review current and emerging therapeutic options for hypothyroidism.
  • To evaluate the efficacy and patient preference for combination LT4 and liothyronine (LT3) therapy.
  • To explore novel approaches including regenerative medicine and tissue-specific T3 analogs.

Main Methods:

  • Review of randomized clinical trials comparing LT4 alone versus LT4+LT3 therapy.
  • Discussion of ongoing research in slow-release LT3 formulations.
  • Examination of advancements in human thyroid organoid transplantation.
  • Analysis of T3 signaling dynamics in specific conditions like metabolic dysfunction-associated fatty liver disease (MAFLD).

Main Results:

  • Combination LT4+LT3 therapy is safe and preferred by patients over LT4 alone.
  • Many patients experience improved quality of life and cognition with LT4+LT3.
  • New slow-release LT3 formulations and thyroid organoid transplantation are under investigation.
  • Tissue-specific T3-like molecules show success in clinical trials for MAFLD.

Conclusions:

  • Combination LT4+LT3 therapy represents a valuable option for symptomatic hypothyroidism patients.
  • Regenerative medicine and targeted T3 analogs offer future therapeutic avenues.
  • Understanding tissue-specific T3 signaling is crucial for personalized hypothyroidism management.